Monitor for potential dilutive financing given cash runway only through Q4 2026; Phase 1 updates in 2H 2026 could provide catalyst if positive, but near-term funding overhang likely weighs on the stock.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $0.2960entry
- T+1 · 3mo ago −3.72%α −3.24% · $0.2850
- T+5 · 3mo ago −2.50%α −1.13% · $0.2886
- T+20 · 2mo ago +3829.05%α +3831.05% · $11.63
- T+60 · 8d ago −41.62%α −38.58% · $0.1728
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M is expected to fund operations only through Q4 2026, raising near-term financing concerns. Two Phase 1 TriKE trials are enrolling, with updates expected in 2H 2026.
Key Financial Metrics
Key Facts
- EPS -$0.11 vs consensus -$0.08 (-37.5% miss)
- Cash and equivalents $5.1M as of June 30, 2026, sufficient through Q4 2026
- R&D expenses $1.1M (up from $0.4M YoY), SG&A $3.4M (up from $1.1M YoY)
- Net loss $4.5M vs $30.2M in prior year (improvement due to non-recurring $28.7M Greenshoe liability in 2025)
- Phase 1 GTB-3650 (CD33) and GTB-5550 (B7-H3) trials enrolling; updates expected 2H 2026
Financial Impact
EPS miss of 37.5% on a small base; cash burn rate suggests need for financing within ~5 months
Risk Factors
- Cash runway limited to Q4 2026, likely requiring additional financing
- Clinical trial enrollment delays or negative data
- Potential Nasdaq delisting if stock price remains low
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345280 |
Track record
12 reports on GTBP
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
- Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
- Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
- Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
- Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
- Aug 14, 202613w ago Press Release Bearish 5/10 Viewing Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
- May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
- Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers